Health Care › Orthopedic, Prosthetic And Surgical Appliances And Supplies
ZBH Stock Price Correlated With Zimmer Biomet Holdings Financials
External Links ⌄
Income Statement
Cash Flow
Balance Sheet
ZBH Income Statement
Enable JavaScript and reload
Revenue, Net:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
ZBH Cash Flow
Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:
ZBH Balance Sheet
Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:
Major Holders (from 13F filings)
Investment Type
Change
Value (x$1000)
increase or decrease
Vanguard Group
24,132,563 sh
-232,201 sh
-1%
-1%
$3,513,701
$365,774
Blackrock.
22,098,606 sh
294,330 sh
1%
1%
$3,217,559
-$2,776,827,556
Price T Rowe Associates /Md/
9,223,132 sh
-1,208,907 sh
-12%
-12%
$1,343
-$5
State Street
9,056,896 sh
318,082 sh
4%
4%
$1,320,827
$189,701
Invesco.
6,712,430 sh
3,551,018 sh
112%
112%
$977,329
-$402,102,705
Dodgex
4,864,500 sh
-82,950 sh
-2%
-2%
$708,271
$77,471
Primecap Management Co/Ca/
4,862,792 sh
-72,120 sh
-1%
-1%
$708,023
$70,432
Geode Capital Management
4,413,445 sh
98,278 sh
2%
2%
$640,904
$84,660
Franklin Resources
4,209,099 sh
-287,970 sh
-6%
-6%
$612,844
$142,675
American Century Companies
4,011,555 sh
-1,043,640 sh
-21%
-21%
$584,082
-$69,034
JPMorgan Chase
3,871,730 sh
-79,645 sh
-2%
-2%
$563,725
$53,208
Morgan Stanley
3,286,497 sh
4,709 sh
0%
0%
$478,515
$54,509
Victory Capital Management
2,936,316 sh
-5,667 sh
0%
0%
$427,527
$47,423
Neuberger Berman Group
2,649,387 sh
63,759 sh
2%
2%
$385,712
-$329,300,541
Northernrp
2,540,195 sh
55,695 sh
2%
2%
$369,853
$48,856
Capital Research Global Investors
2,358,454 sh
100,139 sh
4%
4%
$343,391
$51,617
Allspring Global Investments Holdings
2,151,003 sh
-197,262 sh
-8%
-8%
$313,186
$9,790
Boston Partners
2,085,873 sh
-180,000 sh
-8%
-8%
$303,567
$10,741
Van Eck Associates
1,935,708 sh
344,858 sh
22%
22%
$282
$77
Legal & General Group Plc
1,903,994 sh
219,309 sh
13%
13%
$277,221
$59,561
COMPANY PROFILE
1.
Business
We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products. We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.
The words “Zimmer Biomet,” “we,” “us,” “our,” “the Company” and similar words refer to Zimmer Biomet Holdings, Inc. and its subsidiaries. “Zimmer Biomet Holdings” refers to the parent company only. In 2015, we completed our merger with LVB Acquisition, Inc., the parent company of Biomet, Inc. (“Biomet”).
Risks and Uncertainties - Our results have been and are expected to continue to be impacted by the COVID-19 global pandemic. The vast majority of our net sales are derived from products used in elective surgical procedures which continue to be deferred due to precautions in certain markets and staffing shortages. The consequences of COVID-19 continue to be extremely fluid and there are many market dynamics that are difficult to predict. The COVID-19 pandemic may have an unfavorable effect on our financial position, results of operations and cash flows in the near term.
Planned Spinoff - On February 5, 2021, we announced our intention to pursue a plan to spin off our Spine and Dental businesses into a new public company named ZimVie Inc. (“ZimVie”). The planned transaction is intended to benefit our stockholders by enhancing the focus of both Zimmer Biomet and ZimVie to meet the needs of patients and customers and, therefore, achieve faster growth and deliver greater value for all stakeholders. The transaction is intended to qualify as a tax-free distribution, for U.S. federal income tax purposes, to U.S. stockholders of new publicly traded stock in ZimVie. The expected completion date of the spinoff is March 1, 2022. Our Board of Directors has declared a pro rata dividend of 80.3% of the outstanding common stock of ZimVie to our stockholders of record as of the close of business on February 15, 2022. As a result of the dividend, our stockholders will receive one share of ZimVie common stock for every ten shares of our common stock. Immediately following the dividend, we will retain 19.7% of the outstanding shares of ZimVie common stock, which we intend to divest after the separation in a tax-efficient manner.
Business
We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products. We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.
The words “Zimmer Biomet,” “we,” “us,” “our,” “the Company” and similar words refer to Zimmer Biomet Holdings, Inc. and its subsidiaries. “Zimmer Biomet Holdings” refers to the parent company only. In 2015, we completed our merger with LVB Acquisition, Inc., the parent company of Biomet, Inc. (“Biomet”).
Risks and Uncertainties - Our results have been and are expected to continue to be impacted by the COVID-19 global pandemic. The vast majority of our net sales are derived from products used in elective surgical procedures which continue to be deferred due to precautions in certain markets and staffing shortages. The consequences of COVID-19 continue to be extremely fluid and there are many market dynamics that are difficult to predict. The COVID-19 pandemic may have an unfavorable effect on our financial position, results of operations and cash flows in the near term.
Planned Spinoff - On February 5, 2021, we announced our intention to pursue a plan to spin off our Spine and Dental businesses into a new public company named ZimVie Inc. (“ZimVie”). The planned transaction is intended to benefit our stockholders by enhancing the focus of both Zimmer Biomet and ZimVie to meet the needs of patients and customers and, therefore, achieve faster growth and deliver greater value for all stakeholders. The transaction is intended to qualify as a tax-free distribution, for U.S. federal income tax purposes, to U.S. stockholders of new publicly traded stock in ZimVie. The expected completion date of the spinoff is March 1, 2022. Our Board of Directors has declared a pro rata dividend of 80.3% of the outstanding common stock of ZimVie to our stockholders of record as of the close of business on February 15, 2022. As a result of the dividend, our stockholders will receive one share of ZimVie common stock for every ten shares of our common stock. Immediately following the dividend, we will retain 19.7% of the outstanding shares of ZimVie common stock, which we intend to divest after the separation in a tax-efficient manner.
Free historical financial statements for Zimmer Biomet Holdings Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 54 quarters since 2010. Compare with ZBH stock chart to see long term trends.
Data imported from Zimmer Biomet Holdings Inc SEC filings. Check original filings before making any investment decision.